Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISTH 2022 | International collaborations working to improve hemophilia care

Brian O’Mahony • 11 Jul 2022
ISTH 2022
Hemophilia

Brian O’Mahony, Irish Haemophilia Society, Dublin, Ireland, highlights the importance of international collaborations working to improve hemophilia care, including the World Federation for Hemophilia (WFH), the European Haemophilia Consortium (EHC), and other humanitarian aid programs. This interview took place at the 30th Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2022 held in London, UK.

More from Brian O’Mahony

Empowering patients with hemophilia to make choices about gene therapy
0:50
Empowering patients with hemophilia to make choices about gene therapy
Brian O’Mahony • 11 Jul 2022
The role of social media in patient advocacy in hemophilia
0:44
The role of social media in patient advocacy in hemophilia
Brian O’Mahony • 11 Jul 2022
The importance of liver health in patients participating in hemophilia gene therapy clinical trials
0:43
The importance of liver health in patients participating in hemophilia gene therapy clinical trials
Brian O’Mahony • 11 Jul 2022
Key steps to improve opportunities for gene therapy in patients with hemophilia
0:31
Key steps to improve opportunities for gene therapy in patients with hemophilia
Brian O’Mahony • 11 Jul 2022

Related Videos

Importance of long-term surveillance after gene therapy in patients with hemophilia
5:45
Importance of long-term surveillance after gene therapy in patients with hemophilia
Radek Kaczmarek • 20 Jul 2026
Emerging non-AAV gene therapy strategies in hemophilia: opportunities and challenges
4:58
Emerging non-AAV gene therapy strategies in hemophilia: opportunities and challenges
Radek Kaczmarek • 20 Jul 2026
Ongoing challenges associated with using AAV-based gene therapy in hemophilia
5:18
Ongoing challenges associated with using AAV-based gene therapy in hemophilia
Radek Kaczmarek • 20 Jul 2026
Understanding potential malignancy risk following AAV gene therapy in hemophilia
7:23
Understanding potential malignancy risk following AAV gene therapy in hemophilia
Radek Kaczmarek • 20 Jul 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals